Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
2 vehicles on file, newest listing first
none appears on more than one · 1 vehicle carry no counterparty filing we have read
1 person on two or more of them
Zhiqiang Du is a director of Southern Cross Acquisition I Corp. (NASDAQ: NCOOU), a special purpose acquisition company that priced its $100 million IPO in July 2026 under the leadership of Chairwoman and CEO Ally Tong Zhang and CFO Siu Wai Lam. Du was appointed to the board alongside fellow directors Qian Xu and Zhuo Liang, effective July 21, 2026, and serves on both the audit committee and the compensation committee. He has been designated as an "audit committee financial expert" under SEC guidelines. On July 16, 2026, the company's sponsor, Southern Cross Acquisition I Sponsor Corp., transferred 2,000 ordinary shares to Du, establishing his direct ownership stake in the issuer. The SPAC is pursuing a generalist search strategy with a particular focus on combination targets based in China. Du is based in Singapore, while the sponsor is incorporated in the Cayman Islands and its sole shareholder and director, Dong Chen, resides in Hong Kong.
Born in 1972 and holding American nationality, Du built his career at the intersection of medicine and pharmaceutical research and development. He earned a seven-year clinical medicine master's degree from China Medical University, followed by a PhD in biology from Texas Tech University and a postdoctoral fellowship at MD Anderson Cancer Center in Houston. He was recognized as the fifth "Zhangjiang Outstanding Talent" in Shanghai, a designation reflecting his prominence in the region's life sciences sector. From 2009 to 2018, Du held key R&D positions at several multinational pharmaceutical companies operating in Asia, including Novartis China, Johnson & Johnson Pharmaceuticals China, and Amgen Asia Pacific. His research spanned endocrine metabolism, cardiovascular, and oncology therapeutic areas.
Prior to his current roles, Du served as Vice President of R&D at Shanghai Renhui Biopharmaceutical Co., Ltd. He has also been identified as Vice President at Shanghai Benemae Pharmaceutical Corp. In September 2021, he joined Tonghua Dongbao Pharmaceutical Co., Ltd. as Deputy General Manager, a position he held as of 2025. His career reflects deep expertise in pharmaceutical R&D leadership across both multinational and Chinese biopharmaceutical organizations, making him a valuable addition to the Southern Cross Acquisition I board as it seeks a business combination target, particularly in the China-focused life sciences and healthcare sectors.
This record is keyed to SEC CIK 0002144426 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 4 institutional-holder rows on these vehicles, under 4 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.